Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment
Open Access
- 22 May 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 133 (12), 1462-1469
- https://doi.org/10.1097/cm9.0000000000000844
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare group of extra-nodal non-Hodgkin lymphoma which is confined to the central nervous system or eyes. This article aims to present a brief profile of PCNSL diagnosis and treatment in immunocompetent patients. The authors retrieved information from the PubMed database up to September 2019. The annual incidence of PCNSL increased over the last four decades. The prognosis of PCNSL has improved mainly due to the introduction and wide-spread use of high-dose methotrexate, which is now the backbone of all first-line treatment polychemotherapy regimens. Gene expression profiling and next-generation sequencing analyses have revealed mutations that induce activation of nuclear factor-κB, B cell antigen receptor, and Janus kinases/signal transducer and activator of transcription proteins signal pathways. Some novel agents are investigated in the treatment of relapsed PCNSL including immunotherapy and targeted therapy. In particular, lenalidomide and ibrutinib have demonstrated durable efficiency. Treatment of PCNSL has evolved in the last 40 years and survival outcomes have improved in most patient groups, but there is still room to improve outcome by optimizing current chemotherapy and novel agents.Keywords
This publication has 73 references indexed in Scilit:
- Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)Journal of Clinical Oncology, 2013
- CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphomaBlood, 2013
- Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System LymphomasClinical Cancer Research, 2012
- Age, gender, and racial differences in incidence and survival in primary CNS lymphomaBritish Journal of Cancer, 2011
- Rituximab monotherapy for patients with recurrent primary CNS lymphomaNeurology, 2011
- Primary CNS Lymphoma—Radiation-Free Salvage Therapy by Second Autologous Stem Cell TransplantationTransplantation and Cellular Therapy, 2011
- An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphomaAnnals of Oncology, 2011
- Protein Biomarker Identification in the CSF of Patients With CNS LymphomaJournal of Clinical Oncology, 2008
- Treatment of Relapsed Central Nervous System Lymphoma with High-Dose MethotrexateClinical Cancer Research, 2004
- Primary intracerebral malignant lymphoma: report of 248 casesJournal of Neurosurgery, 2000